Dr. Rimawi Discusses Patient Selection in HER2+ Breast Cancer

Mothaffar F. Rimawi, MD
Published: Monday, Dec 18, 2017



Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses patient selection in the treatment of HER2-positive breast cancer.

In the era of precision medicine, many trials have shown that patients need to be better selected for targeted treatments, says Rimawi.

In a study presented at the 2017 San Antonio Breast Cancer Symposium, it was concluded that the benefit of anti-HER2 treatment seen in patients who are HER2-positive does not extend beyond that population. This is a win for precision medicine, says Rimawi, as it demonstrates that certain populations need less treatment than others.
 
SELECTED
LANGUAGE


Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses patient selection in the treatment of HER2-positive breast cancer.

In the era of precision medicine, many trials have shown that patients need to be better selected for targeted treatments, says Rimawi.

In a study presented at the 2017 San Antonio Breast Cancer Symposium, it was concluded that the benefit of anti-HER2 treatment seen in patients who are HER2-positive does not extend beyond that population. This is a win for precision medicine, says Rimawi, as it demonstrates that certain populations need less treatment than others.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x